Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

 2 years ago       259 Views

Zacks Equity Research Novo Nordisk A/S (NVO - Free Report) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.

Last week, Fiasp received marketing authorization from Health Canada.

Meanwhile, a regulatory application has been filed in the U.S., Switzerland, Australia, Brazil, South Africa and Argentina.

We note that Novo Nordisk has a strong presence in the diabetes care market with a global value share of 27%, supported by one of the broadest diabetes portfolios in the industry comprising drugs like Victoza, Levemir and modern insulins.

Loss of exclusivity for products like NovoRapid/NovoLog and NovoLog Mix/NovoMix, along with intensifying competition in the diabetes market remains a major concern.

Novo Nordisk A/S Price and Consensus | Novo Nordisk A/S Quote Novo Nordisk carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank stocks here.

Sucmapo’s earnings estimates were stable at $1.22 for 2016 but have increased from $1.30 to $1.74 for 2017 over the last 60 days.

The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.

As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain.

Author: @DailyCupofYoga

Source: zacks.com